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Key questions
What is already known about this subject?
 ► In patients with atrial fibrillation, bradycardia may 
lead to excess associated morbidity and subse-
quently pacemaker implantation.
What does this study add?
 ► We found important risk factors of pacemaker im-
plantation in patients with atrial fibrillation and 
developed a risk score to predict pacemaker im-
plantation in these patients.
How might this impact on clinical practice?
 ► The risk factors are important knowledge for risk 
stratification of patient with atrial fibrillation. The 
clinical utility of the risk score requires further 
investigation.
AbstrAct
Objectives To identify risk factors and to develop a 
predictive risk score for pacemaker implantation in 
patients with atrial fibrillation (AF).
Methods Using Danish nationwide registries, patients 
with newly diagnosed AF from 2000 to 2014 were 
identified. Cox proportional- hazards regression computed 
HRs for risk factors of pacemaker implantation. A logistic 
regression was used to fit a prediction model for 3- month 
risk of pacemaker implantation and derived a risk 
score using 80% of the data and its predictive accuracy 
estimated using the remaining 20%.
Results Among 155 934 AF patients included, the median 
age (IQR) was 75 (65–83) and 51.3% were men. During a 
median follow- up time of 3.4 (1.2–5.0) years, 8348 (5.4%) 
patients received a pacemaker implantation. Risk factors 
of pacemaker implantation were (in order of highest risk 
first) age above 60 years, congenital heart disease, heart 
failure at age under 60 years, prior syncope, valvular AF, 
hypertension, ischaemic heart disease, male sex and 
diabetes mellitus. The derived risk score assigns points 
ranging from 1 to 14 to each of these risk factors. The 
3- month risk of pacemaker implantation increased from 
0.4% (95% CI: 0.2 to 0.8) at 1 point to 2.6% (95% CI: 
1.9 to 3.6) at 18 points. Area under the receiver operator 
characteristics curve was 62.9 (95% CI: 60.3 to 65.5).
Conclusion We highlighted risk factors of pacemaker 
implantation in newly diagnosed AF patients and created a 
risk score. The clinical utility of the risk score needs further 
investigation.
IntROduCtIOn
Patients with atrial fibrillation (AF) of all types 
(paroxysmal, persistent and permanent) have 
an increased risk of symptomatic bradycardia 
due to sinus node and atrial remodelling by 
disease progression and the use of rhythm 
and rate- lowering drugs.1 2 Bradycardia may 
lead to excess associated morbidity, trau-
matic falls and reduced quality of life neces-
sitating a permanent pacemaker (PPM).3 4 
Furthermore, AF is a prevalent condition in 
patients with bradycardia such as sick sinus 
node syndrome (SSS) and atrioventricular 
(AV) blocks.1 5 Previous studies have focused 
on rhythm- lowering or rate- lowering induced 
symptomatic bradycardia requiring pacing, 
but research on clinical risk factors for PPM 
is lacking.6–8 AF patients with a PPM have a 
high presence of concomitant cardiovascular 
comorbidities.9 We hypothesised that these 
comorbidities possibly contribute to cardiac 
conduction disease progression leading to a 
PPM. By improving risk stratification of AF 
patients, there is the potential to enhance 
rhythm monitoring and timing of PPM and 
reduce bradycardia- related morbidity. The 
purpose of the study was to identify risk 
factors for PPM, predict the absolute risk of 
PPM and to construct and internally validate 
a risk score to use as a clinical decision tool in 
a newly diagnosed AF cohort.
MetHOds
A cohort study using the Danish nationwide 
registers was conducted. At birth or immi-
gration, all Danish residents are provided 
with a unique and permanent civil registra-
tion number enabling cross- linking between 
nationwide registers on the individual level. 
The following registers were used to identify 
patient characteristics, procedures including 
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PPM, concomitant pharmacotherapy and comorbidities: 
The Civil Registration System, The Danish Register of 
Causes of Death, The Danish National Patient Register 
and The Danish Register of Medicinal Product Statistics. 
The Civil Registration System includes data on age, sex 
and vital status. The Danish National Patient Register has 
information on date of hospital admissions in Denmark 
since 1978, date of discharge with one primary diagnosis 
and one or more secondary diagnoses defined by the 
International Classification of Diseases the 10th revision 
(ICD-10) since 1994. Procedures have been registered 
since 1996 and coded by The Nordic Classification of 
Surgical Procedures. The Danish Register of Medicinal 
Product Statistics holds information on drug prescrip-
tions redeemed since 1994. The international anatomical 
therapeutic (ATC) chemical classifies each drug.
study population
The Danish National Patient Register was used to identify 
patients with a primary or secondary diagnosis of newly 
diagnosed AF (ICD-10: I48) including both inpatient or 
outpatients from 1 January 2000 to 31 December 2014. 
Follow- up stopped on 31 December 2015. In Denmark, 
some AF patients are exclusively treated in the primary 
healthcare sector, and thus have an unknown onset of 
AF before admitted or referred to an outpatient clinic 
with an AF diagnosis. To exclude AF patients treated 
only in primary care, ATC codes were used to identify 
and exclude patients who had previously been treated 
with digoxin, antiarrhythmic drugs (amiodarone, drone-
darone, class- 1c: flecainide, propafenone) and up to 
1 year prior treatment of vitamin K- antagonists or non- 
vitamin K oral anticoagulants. Patients who had under-
gone prior cardioversion and ablation procedures for 
AF were excluded. Patients with prior PPM identified by 
procedure codes were also excluded.
Outcomes of pacemaker implantation and all-cause mortality
Procedure codes were used to identify the date of first- 
time procedure codes of PPM. The procedure codes have 
previously been validated.10 Date of death was obtained 
from the Danish Civil Registration system.
Baseline comorbidity, procedures and cardiovascular 
pharmacotherapy
Comorbidities at baseline were identified by ICD-10 codes 
using primary and secondary diagnoses in both inpatient 
and outpatient, up to 5 years prior to inclusion. Comor-
bidities were ischaemic heart disease (IHD), heart failure 
(HF), diabetes mellitus (DM), chronic kidney disease, 
chronic obstructive pulmonary disease, autoimmune 
disorders, valvular AF, congenital heart diseases (CHD), 
hypertension and prior syncope. Diagnosis of bradycardia 
at baseline was also identified. Procedures were also iden-
tified up to 5 years from inclusion. ATC codes were used 
to identify prescription drugs claimed at pharmacies 180 
days prior to the date of inclusion. Antidiabetic drugs 
were used as a proxy for DM. Hypertension was defined 
as the use of a combination of at least two of the seven 
different antihypertensive drugs classes at the same time. 
All ATC, ICD and procedure codes used are available in 
online supplementary table 1.
statistical analyses
All patients were followed from date of first- time admission 
or outpatient visit with an AF diagnosis until date of PPM 
implantation, death, emigration, 5 years from baseline or 
end of follow- up (December 2015), whichever came first. 
Age was categorised into four groups: ≤60, 61–70, 71–80 
and ≥81 years of age. The cumulative incidence func-
tions (ie, risk) of PPM and competing death without PPM 
within 5 years were estimated using the Aalen- Johansen 
estimator. Cause- specific Cox proportional- hazards 
regression analyses were used to estimate adjusted HRs 
for PPM and all- cause mortality with 95% CI. Propor-
tional hazard assumptions were assessed graphically by 
Schoenfeld residual plots. An interaction between HF 
and age was found and was thus entered into the cause- 
specific Cox models and the prediction model as such. 
To clarify indications for PPM, type of PPM and brady-
cardia hospitalisations up to 30 days prior to PPM proce-
dure were identified. Rate- lowering and antiarrhythmic 
drugs prescriptions claimed up to 3 months prior PPM 
procedure were identified. AV node ablation procedures 
were identified 1 month prior to PPM procedure and up 
to 2 months post PPM procedure.
For the logistic prediction model, to avoid predicting 
on events during initial AF hospitalisation, the follow- up 
started from two independent contributing cohorts. 
Either first- time AF discharge diagnosis or first- time AF at 
the outpatient visit date—thereby excluding patients who 
died or received a PPM during first AF hospitalisation. To 
construct and evaluate the prediction model, the cohort 
was split into a learning (80% of the data) and a valida-
tion cohort (20%). The learning cohort was used to esti-
mate to what extent each risk factor could independently 
predict the 3- month risk of PPM; 3 months were chosen 
because covariates used were not informative enough 
to make long- term predictions. Covariates were chosen 
based on availability and a priori knowledge of suspected 
risk factors of PPM. The covariates chosen were sex, age, 
hypertension, IHD, DM, HF, syncope and CHD. The 
prediction model was estimated using a logistic regression 
adjusted for calendar year. There was no censoring issue 
as the data did not contain any loss to follow- up within 
the first 3 months. The points associated with each risk 
factor were defined by multiplying by 10 and rounding 
the corresponding parameter. The risk score was defined 
as the sum of these points. The validation cohort was used 
to evaluate the performance. Plots of the distribution of 
risk points and their corresponding ‘observed’ 3 months 
risk of PPM illustrate the discriminative performance in 
the validation cohort. Observed risks, true positive, false 
positive rates, positive and negative predictive values 
were computed as empirical proportions and associated 
CIs were computed using the exact binomial method. 
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Figure 1 Flowchart of study inclusion. NOAC, non- vitamin 
K anticoagulants; VKA, vitamin- K antagonist.
Table 1 Baseline characteristics
Overall
n 155 934
Sex, male (%) 79 969 (51.3)
Age (median (IQR)) 75 (65–83)
Comorbidities, n (%)
  Ischaemic heart disease 33 114 (21.2)
  Heart failure 26 416 (17.0)
  Valvular atrial fibrillation 1896 (1.2)
  Congenital heart disease 409 (0.3)
  Chronic obstructive pulmonary disease 17 660 (11.3)
  Autoimmune disorders 1708 (1.1)
  Chronic kidney disease 6265 (4.0)
  Syncope 8681 (5.6)
  Hypertension 61 898 (39.7)
  Sick sinus node (%) 1381 (0.9)
  AV block grade 2 (%) 303 (0.2)
  AV block grade 1 (%) 221 (0.1)
  Bradycardia, unspecified (%) 1133 (0.7)
Procedures
  PCI 4776 (3.1)
  CABG 2335 (1.5)
Pharmacotherapy
  Loop diuretics 30 560 (19.6)
  Non- loop diuretics 47 638 (30.6)
  RAS- inhibitors 47 045 (30.2)
  Betablocker 39 768 (25.5)
  CCBs 34 715 (22.3)
  ASA 52 198 (33.5)
Autoimmune disorders are systemic lupus erythematosus, 
rheumatoid arthritis and scleroderma.
ASA, acetylsalicylic acid; AV, atrioventricular; CABG, coronary 
artery bypass graft; CCBs, calcium channel blockers; PCI, 
percutaneous coronary intervention; RAS- inhibitors, renin- 
angiotensin inhibitors.
Receiver operator characteristics (ROC) curves and area 
under the curve (AUC) were also computed, with 95% CI, 
for quantifying predictive accuracy of the 3- month and 
5- year risk of PPM. We used Delong’s method for the 
3- month outcome and an appropriate method to handle 
censored data for the 5- year outcome.11 12 We repeated 
the analysis using the entire data for both building and 
evaluating the risk score. A sensitivity analysis excluding 
cardiac resynchronisation therapy (CRT) as an outcome 
was performed in the Cox model to determine if the risk 
factors remained the same. A two- sided p- value<0.05 was 
considered statistically significant. Data management 
and statistical analyses were conducted using R statistics 
(Team RC. R: A Language and Environment for Statistical 
Computing. Vienna, Austria: R Foundation for Statistical 
Computing; 2018).
Results
A total of 155 934 patients with newly diagnosed AF were 
included between 2000 and 2014 (figure 1) with a median 
follow- up time of 3.4 years (1.2–5.0). Overall median 
age (IQR) was 75 (65‒83) years, and 51.3% (n=79 969) 
were male. Baseline characteristics are shown in table 1. 
During follow- up, 8348 (5.4%) patients received a PPM 
implantation (figure 2). At baseline, 1381 (0.9%) had 
SSS, and 1605 (1.0%) received a PPM during hospitalisa-
tion for first- time AF.
Risk factors
Several risk factors were independently associated with 
the rate of PPM implantation. An interaction with HF 
and age was significant (p- value<0.001) and thus results 
are shown in table 2 stratified by the presence of HF. 
The rate of PPM for AF patients with HF and without HF 
increased significantly with age, and age >80 years without 
HF lead to the largest adjusted risk factor (HR (95% CI): 
4.17 (3.77 to 4.61)). CHD was highly associated with PPM 
(2.42 (1.74 to 3.38)) and HF was found to be a signifi-
cant risk factor particularly among AF patients aged ≤60 
years (2.34 (1.92 to 2.85)). Other important risk factors 
included prior syncope (1.92 (1.79 to 2.06)), valvular AF 
(1.39 (1.19 to 1.63)), hypertension (1.31 (1.25 to 1.37)), 
IHD (1.19 (1.13 to 1.26)), male sex (1.19 (1.13 to 1.24)) 
and DM (1.17 (1.09 to 1.25)) (table 2).
In the sensitivity analysis excluding CRT implantation 
as an outcome, the same risk factors were significantly 
associated with a higher rate of PPM although the rate of 
PPM decreased in patients with HF and age ≤60 years to 
an HR of 1.87 (1.50 to 2.33).
Of the 8348 patients receiving a PPM, of those 
receiving a pacemaker, the majority were dual chamber 
(48.0%) and single chamber ventricular (30.5%), 44.0% 
of patients had a diagnosis of SSS, 19.6% had a diagnosis 
of third- degree AV block and 14.0% had a diagnosis of 
unspecified bradycardia (online supplementary table 2). 
In those receiving a PPM, treatment with betablockers 
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Figure 2 Cumulative incidence of permanent pacemaker 
and all- cause mortality for 5 years follow- up time in years 
since admission or outpatient date for newly diagnosed atrial 
fibrillation (AF).
Table 2 Cause- specific Cox model for pacemaker and 
death
Variable
Adjusted HR for 
pacemaker (95% CI)
Adjusted HR for 
death (95% CI)
Sex (male) 1.19 (1.13 to 1.24) 1.11 (1.09 to 1.13)
Interaction: heart failure and age (p<0.001)   
  Age ≤60 years, no 
heart failure
Ref Ref
  Age 61–70 years, 
no heart failure
2.26 (2.03 to 2.51) 2.49 (2.36 to 2.63)
  Age 71–80 years, 
no heart failure
3.29 (2.98 to 3.64) 5.06 (4.82 to 5.32)
  Age >80 years, no 
heart failure
4.17 (3.77 to 4.61) 11.69 (11.14 to 12.27)
  Age ≤60 years, if 
heart failure
2.34 (1.92 to 2.85) 2.44 (2.20 to 2.70)
  Age 61–70 years, 
if heart failure
2.68 (2.29 to 3.13) 4.71 (4.39 to 5.04)
  Age 71–80 years, 
if heart failure
3.84 (3.39 to 4.35) 8.31 (7.85 to 8.78)
  Age >80 years, if 
heart failure
3.51 (3.10 to 3.97) 16.59 (15.77 to 17.46)
Comorbidities   
  Autoimmune 
disorder
0.86 (0.69 to 1.08) 1.35 (1.26 to 1.45)
  Chronic kidney 
disease
1.01 (0.91 to 1.13) 1.93 (1.87 to 2.00)
  Diabetes mellitus 1.17 (1.09 to 1.25) 1.25 (1.22 to 1.29)
  Ischaemic heart 
disease
1.19 (1.13 to 1.26) 1.05 (1.03 to 1.07)
  Hypertension 1.31 (1.25 to 1.37) 1.01 (0.99 to 1.02)
  Valvular AF 1.39 (1.19 to 1.63) 0.71 (0.65 to 0.78)
  Syncope 1.92 (1.79 to 2.06) 1.02 (0.98 to 1.05)
  Congenital heart 
disease
2.42 (1.74 to 3.38) 0.91 (0.72 to 1.16)
Procedures    
  CABG 0.86 (0.73 to 1.01) 0.60 (0.55 to 0.65)
  PCI 1.09 (0.97 to 1.22) 0.72 (0.68 to 0.76)
The HRs are estimated using 5 years of follow- up for the rate of 
pacemaker and all- cause mortality.
AF, atrial fibrillation; CABG, coronary artery bypass graft; PCI, 
percutaneous coronary intervention.
Figure 3 Forest plot. OR and corresponding risk points 
estimated from the logistic model which models the 3- month 
risk of PPM given all the risk factors. The model includes 
an interaction between age and heart failure. Summing the 
points corresponding to each risk factor present defines 
the risk score. AF, atrial fibrillation; CHD, congenital heart 
disease; IHD, ischaemic heart disease.
were the most common (39.9%) followed by digoxin 
(16.1%), verapamil or diltiazem (5.1%), amiodarone 
(3.9%) and flecainide or propafenone (1.0%). AV node 
ablations were rare (0.1%).
Risk score
During the 3 months of follow- up after discharge for AF 
or first outpatient visit for AF, 2148 patients received a 
PPM. The cumulative incidence (95% CI) of PPM showed 
a steady increase from 0 to 3 months reaching 1.45% 
(1.38 to 1.51) (online supplementary figure 1).
In the 3- month prediction model, 148 586 patients 
were included excluding 7300 patients that either died 
or received a PPM during initial hospitalisation (online 
supplementary table 3) and divided into a learning 
(n=1 18 869) and a validation cohort (n=29 717). The 
logistic model estimated using the learning cohort 
resulted in risk points given to each risk factor ranging 
from 1 to 14, with age contributing up to 14 points (age 
>80, if no HF) (figure 3). The patient risk score was 
derived by summing the points corresponding to each 
risk factor (online supplementary table 4).
The validation cohort showed increasing risk of PPM 
with increasing risk point (95% CI), from 0.4% (0.2 to 
0.8) at 1 point to 2.6% (1.9 to 3.6) at 18 points (figure 4). 
See online supplementary figure 2 for similar results 
obtained from the full cohort. Discrimination perfor-
mances by age group are provided in online supple-
mentary figure 3. The AUC estimated (95% CI) on the 
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Figure 4 Distribution of risk points and 3- month risk of 
permanent pacemaker in the validation cohort. Displayed are 
the estimated risk (dots, left axis) with 95% CIs and numbers 
of subjects per risk points (bars, right axis). The dashed 
line displays the risk which is predicted by the logistic 
model. The dotted line displays the estimate of the marginal 
risk. A triangle indicates that the CI is truncated. Data not 
shown when less than 200 subjects are observed with the 
corresponding number of points.
Figure 5 Receiver operator characteristics curve estimated 
from the validation cohort for 3 months prediction. Area under 
the curve with 95% CI for the risk score and age alone.
validation cohort was 62.9 (60.3 to 65.5) (figure 5), which 
was close to the ‘apparent’ AUC estimated on the learning 
cohort 64.0 (62.9 to 65.1). The AUC of the risk score 
performed significantly better than the AUC with age 
alone (p<0.001). Online supplementary figure 4 shows 
the AUC for 5- year prediction. It also shows that the risk 
score performed significantly better than age alone for 
5- year prediction (p<0.001). The estimated true positive 
rates, false positive rates, positive predictive values and 
negative predictive values for each cut- off are in online 
supplementary table 5. At 20 points, the positive predic-
tive value was 2.5% (1.8 to 3.5) and negative predictive 
value was 98.6% (98.5 to 98.8).
dIsCussIOn
Main findings
To our knowledge, this is the largest cohort study to 
determine important risk factors for PPM and the first 
study to produce a 3- month risk score predicting PPM 
risk in patients with newly diagnosed AF. Significant 
covariates were identified as risk factors of PPM: age >60 
years, CHD, age ≤60 years and HF, prior syncope, valvular 
AF, hypertension, IHD, male sex and DM. A risk score 
was produced and internally validated to predict PPM 
implantation in a 3- months follow- up.
Multiple treatment options are available to treat heart 
rate and rhythm in AF patients: pulmonary vein abla-
tion, antiarrhythmic medication or rate control medica-
tion. For some patients, rate or rhythm control may be 
insufficient and selected patients may undergo AV node 
ablation with permanent pacing.13 In our study, AV node 
ablation and CRT implantation was rare, most patients 
receiving a PPM received a dual chamber pacemaker and 
single ventricular pacemaker, and most of the patients 
had a bradycardia diagnosis, thus we think the majority 
of PPMs was placed to treat bradycardia. A PPM implan-
tation relies on the decision making by the treating physi-
cian considering many factors influencing PPM risk; our 
findings suggest that certain clinical risk factors affect the 
need of pacing in newly diagnosed AF patients.
Risk factors
Age is a well- known risk factor of bradycardia14 and older 
patients with AF might be more susceptible for bradyar-
rhythmic side- effects of AV- blocking medication15 poten-
tially leading to increased risk of PPM. Another important 
risk factor of PPM was CHD. Patients with AF and concom-
itant CHD are a heterogenetic group that have often had 
heart surgery that could lead to bradycardias. However, 
CHD in itself could also increase the risk. Studies have 
shown that types of CHD procedures are associated with 
a different prevalence of SSS and AV block16 suggesting 
that these patients are prone to bradycardias.
HF combined with age ≤60 years was an important risk 
factor. One study (n=362) investigated risk factors of PPM 
placed for symptomatic bradycardia in AF patients; the 
study found an increased risk with HF (OR: 2.72 (95% 
CI: 1.47 to 5.01)) and permanent AF (OR: 2.99 (1.61 to 
5.57)).17 Our study findings support the association with 
HF, although we found the association of PPM with HF 
was primarily in those at younger age. The association of 
PPM with HF in the younger AF cohort may partially be 
explained by the aetiology of the HF, which is more likely 
to be structural and pacing can improve symptoms in 
these patients. Prior diagnosis of syncope was highly asso-
ciated with PPM. Syncope can be a symptom of underlying 
undiagnosed malignant arrhythmia and hospitalisation 
for syncope often leads to vigorous work- up in the search 
for arrhythmias, which in some cases results in PPM.18 
Our study indicates that patients with valvular AF have 
an increased rate of PPM. Valvular surgery, especially 
aortic valve replacement, has, in previous studies, shown 
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to be associated with PPM.19 Hypertension, IHD and DM 
were all associated with PPM implantation. Prior studies 
present similar findings and propose a mechanism 
related to progression of cardiac ischaemia, scar- related 
conduction disease and microangiopathy.20 21 Male sex 
was also associated with PPM implantation. One study 
showed that females are less likely to receive a PPM, 
likely due to their older age at disease presentation and 
decreased body size which potentially increase the risk of 
procedural complications.22 It is unclear from our study 
whether our findings are a sign of under treatment in 
females. We found no association between PPM and auto-
immune disorders or chronic kidney disease.
Risk score
Based on the risk score, one can classify newly diagnosed 
AF patients’ individual as being at ‘high’ or ‘low’ risk of 
PPM within 3 months using several cutoffs. Our results 
provide detailed estimates of the discriminative perfor-
mance that one can expect when using the different 
cutoffs. Overall, the risk score discriminates significantly 
better than age alone, both for 3 months and 5 years. It 
combines nine covariates, by assigning points ranging 
from 1 to 14 to each of them, with age contributing up 
to 14 points (age >80, if no HF) (figure 3). We chose a 
model with better predictive accuracy (3- month model) 
over long- term prediction with poor predictive accuracy 
(5- year model). The discriminative performances that we 
have estimated already provide estimates of the impact 
that defining such guidelines could have, in terms of true 
and false selection of subjects at ‘high risk’. Currently, 
the discriminative abilities of the risk factor in particular 
the true positive prediction was modest and therefore 
future research is warranted to refine the risk score by 
adding new important predictors such as left bundle 
branch block, type of AF and heart rate which could 
possibly improve discriminative abilities. The high nega-
tive predictive value of the risk score may have clinical 
use as it shows that the score can help to identify at very 
low risk of PPM. Most importantly, studies are needed to 
externally validate the risk score. Receiving a pacemaker 
is a valid concern for patients. This risk score could help 
patients and healthcare providers to estimate the risk of 
undergoing PPM procedure. The score might be most 
useful for informing patients of age above 71 years as 
it seems that the risk score has the best discrimination 
ability in that age group (online supplementary figure 
S3).
limitations
This observational study has some important limitations: 
the non- availability of frequency of AF episodes and AF 
type (paroxysmal, persistent or permanent), time of AF 
diagnosis and pacemaker- dependency. We were unable 
to distinguish between AF and atrial flutter; however, it is 
estimated that around 95% of the diagnosis I48 is AF and 
not atrial flutter.23 Too few patients had CHD at baseline 
to make subtypes based on surgical repair. No data were 
available on individual PPM indication. PPM implanta-
tions were rare and the high- risk patients found are rela-
tive to those with low risk. We mainly present results for 
the 3- months outcome as the information used to define 
the risk points are not informative enough to make clin-
ically relevant 5- year risk predictions, as suggested by the 
low AUC of the ROC curve at 5 years and the competing 
risk of death was high during the 5- year follow- up. The risk 
score should be used with caution before external valida-
tion has been performed. It is likely that the sensitivity of 
the diagnosis for bradycardia may not be very high, that 
is, patients with bradycardia do not always get the diag-
nosis registered. Therefore, we did not include it in the 
models. Our use of the date of newly diagnosed AF only 
did not allow us to assess for the potential bradycardia risk 
of rate- lowering or antiarrhythmic drugs prescribed after 
the AF diagnosis, aside from betablockers and calcium 
channel blockers which was categorised in the predictor 
‘hypertension’. Being a registry study, there are no clin-
ical data on blood pressure, laboratory findings, smoking 
status, weight or ECG characteristics such as information 
on conduction abnormality.
COnClusIOn
Overall, the 5- year risk for PPM in newly diagnosed AF 
patients was 5%. We identified nine risk factors of PPM: 
age above 60 years, CHD, age ≤60 years with HF, prior 
syncope, valvular AF, hypertension, IHD, male sex and 
DM. A risk score was produced to predict the absolute 
risk of PPM during a 3- months follow- up after discharge 
or outpatient visit for AF diagnosis. The clinical utility of 
the novel risk score needs further investigation.
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